Health economics assessment of statin therapy initiation thresholds for atherosclerosis prevention in China: a cost-effectiveness analysis
Abstract Background Recent updates to the Chinese guidelines for dyslipidemia management have reduced the 10-year risk threshold for starting statins in the primary prevention of atherosclerotic heart disease. This study aims to evaluate the potential negative effects of different statin initiation...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-01-01
|
| Series: | International Journal for Equity in Health |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12939-025-02391-9 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832585951373688832 |
|---|---|
| author | Tianyu Feng Xiaolin Zhang Jiaying Xu Shang Gao Xihe Yu |
| author_facet | Tianyu Feng Xiaolin Zhang Jiaying Xu Shang Gao Xihe Yu |
| author_sort | Tianyu Feng |
| collection | DOAJ |
| description | Abstract Background Recent updates to the Chinese guidelines for dyslipidemia management have reduced the 10-year risk threshold for starting statins in the primary prevention of atherosclerotic heart disease. This study aims to evaluate the potential negative effects of different statin initiation thresholds on diabetes risk in the Chinese population, while also analyzing their health economic implications. Methods I We developed a microsimulation model based on event probabilities to assess the cost-effectiveness of statin therapy. The model utilized the China-PAR prediction tool for ASCVD risk and incorporated data from a nationally representative survey and published meta-analyses of middle-aged and elderly Chinese populations. Four strategies were evaluated: a 7.5% 10-year risk threshold, the current guideline strategy, and a 15% threshold. For each strategy, we calculated the incremental cost per quality-adjusted life year (QALY) to gain insights into the economic impact of each approach. Result The incremental cost per QALY for the 10% 10-year risk threshold strategy, compared to the untreated, was $52,218.75. The incremental cost per QALY for the guideline strategy, compared to the 7.5% 10-year risk threshold strategy, was $464,614.36. These results were robust in most sensitivity analyses. Conclusion Maintaining the recommended thresholds outlined in the current guidelines for the management of dyslipidemia may represent a cost-effective option for China at present. Variations in statin prices and the risk of statin-induced diabetes have significant impacts on the cost-effectiveness outcomes. |
| format | Article |
| id | doaj-art-df3676b14bce4a9183131b78820fb505 |
| institution | Kabale University |
| issn | 1475-9276 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | BMC |
| record_format | Article |
| series | International Journal for Equity in Health |
| spelling | doaj-art-df3676b14bce4a9183131b78820fb5052025-01-26T12:20:55ZengBMCInternational Journal for Equity in Health1475-92762025-01-012411910.1186/s12939-025-02391-9Health economics assessment of statin therapy initiation thresholds for atherosclerosis prevention in China: a cost-effectiveness analysisTianyu Feng0Xiaolin Zhang1Jiaying Xu2Shang Gao3Xihe Yu4School of Public Health, Chongqin Medical UniversitySchool of Public Health, Jilin UniversitySchool of Public Health, Jilin UniversitySchool of Public Health, Jilin UniversitySchool of Public Health, Jilin UniversityAbstract Background Recent updates to the Chinese guidelines for dyslipidemia management have reduced the 10-year risk threshold for starting statins in the primary prevention of atherosclerotic heart disease. This study aims to evaluate the potential negative effects of different statin initiation thresholds on diabetes risk in the Chinese population, while also analyzing their health economic implications. Methods I We developed a microsimulation model based on event probabilities to assess the cost-effectiveness of statin therapy. The model utilized the China-PAR prediction tool for ASCVD risk and incorporated data from a nationally representative survey and published meta-analyses of middle-aged and elderly Chinese populations. Four strategies were evaluated: a 7.5% 10-year risk threshold, the current guideline strategy, and a 15% threshold. For each strategy, we calculated the incremental cost per quality-adjusted life year (QALY) to gain insights into the economic impact of each approach. Result The incremental cost per QALY for the 10% 10-year risk threshold strategy, compared to the untreated, was $52,218.75. The incremental cost per QALY for the guideline strategy, compared to the 7.5% 10-year risk threshold strategy, was $464,614.36. These results were robust in most sensitivity analyses. Conclusion Maintaining the recommended thresholds outlined in the current guidelines for the management of dyslipidemia may represent a cost-effective option for China at present. Variations in statin prices and the risk of statin-induced diabetes have significant impacts on the cost-effectiveness outcomes.https://doi.org/10.1186/s12939-025-02391-9StatinsCost-effectiveness analysisCHARLSRisk threshold |
| spellingShingle | Tianyu Feng Xiaolin Zhang Jiaying Xu Shang Gao Xihe Yu Health economics assessment of statin therapy initiation thresholds for atherosclerosis prevention in China: a cost-effectiveness analysis International Journal for Equity in Health Statins Cost-effectiveness analysis CHARLS Risk threshold |
| title | Health economics assessment of statin therapy initiation thresholds for atherosclerosis prevention in China: a cost-effectiveness analysis |
| title_full | Health economics assessment of statin therapy initiation thresholds for atherosclerosis prevention in China: a cost-effectiveness analysis |
| title_fullStr | Health economics assessment of statin therapy initiation thresholds for atherosclerosis prevention in China: a cost-effectiveness analysis |
| title_full_unstemmed | Health economics assessment of statin therapy initiation thresholds for atherosclerosis prevention in China: a cost-effectiveness analysis |
| title_short | Health economics assessment of statin therapy initiation thresholds for atherosclerosis prevention in China: a cost-effectiveness analysis |
| title_sort | health economics assessment of statin therapy initiation thresholds for atherosclerosis prevention in china a cost effectiveness analysis |
| topic | Statins Cost-effectiveness analysis CHARLS Risk threshold |
| url | https://doi.org/10.1186/s12939-025-02391-9 |
| work_keys_str_mv | AT tianyufeng healtheconomicsassessmentofstatintherapyinitiationthresholdsforatherosclerosispreventioninchinaacosteffectivenessanalysis AT xiaolinzhang healtheconomicsassessmentofstatintherapyinitiationthresholdsforatherosclerosispreventioninchinaacosteffectivenessanalysis AT jiayingxu healtheconomicsassessmentofstatintherapyinitiationthresholdsforatherosclerosispreventioninchinaacosteffectivenessanalysis AT shanggao healtheconomicsassessmentofstatintherapyinitiationthresholdsforatherosclerosispreventioninchinaacosteffectivenessanalysis AT xiheyu healtheconomicsassessmentofstatintherapyinitiationthresholdsforatherosclerosispreventioninchinaacosteffectivenessanalysis |